NCT01211782 · Phase 2 · WITHDRAWN
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
This trial tests AC-1204, an oral ketogenic compound made from caprylic triglyceride, in people with mild to moderate Alzheimer's disease. The idea is that ketones may provide an alternative fuel source for a brain struggling to use glucose. Researchers measured memory, cognition, daily functioning, and quality of life over six months. This is a Phase 2 trial — testing whether it works and is safe, not yet proven or approved.
You may qualify if
- Males/females between age of 55 -85 years
- MMSE scores between 16-26
- Probable mild to moderate AD
You're excluded if
- Presence of other CNS disorders as alternative causes of dementia
- Type 1 or Type 2 diabetes
- Significant renal/hepatic disease
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2012-12-04